Home›Mitapivat›Mitapivat + Sensitive Cyp3a Substrates With Narrow Therapeutic Index

Does Mitapivat Interact with Sensitive Cyp3a Substrates With Narrow Therapeutic Index?

Mitapivat and Sensitive Cyp3a Substrates With Narrow Therapeutic Index have a contraindicated drug interaction according to U.S. FDA drug labeling data. PYRUKYND induces CYP3A, decreasing concentrations of sensitive substrates with narrow therapeutic index. Avoid concomitant use. The mechanism involves cyp3a induction. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Contraindicated
Mitapivat Class
Pyruvate Kinase Activator
Management
Do not take together
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Mitapivat and Sensitive Cyp3a Substrates With Narrow Therapeutic Index occurs because cyp3a induction. Clinically, this means pyrukynd induces cyp3a, decreasing concentrations of sensitive substrates with narrow therapeutic index. avoid concomitant use. Because of the severity of this interaction, these medications are contraindicated — meaning they should not be taken together under any circumstances. If you are currently taking both, contact your healthcare provider immediately to discuss alternatives.

What To Tell Your Doctor or Pharmacist

If you are taking Mitapivat and your doctor is considering prescribing Sensitive Cyp3a Substrates With Narrow Therapeutic Index (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask about alternative medications that do not interact with your current regimen
  • Ask how frequently you should be monitored while these are co-prescribed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Mitapivat(Aqvesme)+💊 Sensitive Cyp3a Substrates With Narrow Therapeutic Index

Severity & Interaction Details

⛔
contraindicated
Avoid this combination
FDA labeling lists this pair as contraindicated. The risk outweighs the benefit in nearly all cases.
Severity scale
MinorContra
On record
Yes
Drug A class
Pyruvate Kinase Activator
Drug B class
—
Source
NLP:mitapivat

What this means in plain English

PYRUKYND induces CYP3A, decreasing concentrations of sensitive substrates with narrow therapeutic index. Avoid concomitant use.

What the FDA label says

"CYP3A induction"

📖 Source: NLP:mitapivat

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Mitapivat and Sensitive Cyp3a Substrates With Narrow Therapeutic Index against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.